FDA advisors recommend Pfizer RSV vaccine for older adults, despite possible Guillain-Barre risks

Posted on AllSides February 28th, 2023
From The Center
Jarun011 | Istock | Getty Images

The Food and Drug Administration’s independent advisors on Tuesday recommended Pfizer’s RSV vaccine for adults ages 60 and older, despite safety concerns after two people who received the shot developed a rare neurological disorder. 

Though a majority of the FDA committee members backed the vaccine, they wrestled with two separate votes on whether the safety and efficacy data are adequate to support the agency’s approval. 

In the first vote, seven members of the committee said the safety data was adequate for an approval, while four said it was not, and...

Read full story
Some content from this outlet may be limited or behind a paywall.

CNBC

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
115258/88371
See full bias rating for CNBC
Learn about media bias
https://www.cnbc.com/2023/02/28/rsv-vaccine-fda-committee-votes-on-pfizer-shot-for-older-adults.html

More News about Public Health from the Left, Center and Right

From the Left

From the Center

From the Right